January 22, 2026
Now available EXDENSUR
EXDENSUR (depemokimab-ulaa) is an interleukin-5 (IL-5) antagonist, a monoclonal antibody (humanized immunoglobulin G [IgG]1 kappa) indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus.
Please see full prescribing information here.
Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus.
Please see full prescribing information here.